Dystrophic Epidermolysis Bullosa Market Size in the 7MM was ~USD 550 Million in 2023 and it is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Dystrophic Epidermolysis Bullosa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dystrophic Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Dystrophic Epidermolysis Bullosa Market Report
• In September 2025, Krystal Biotech, Inc. announced that the U.S. FDA approved a label update for VYJUVEK® (beremagene geperpavec-svdt), expanding its use to include dystrophic epidermolysis bullosa (DEB) patients from birth. The update also provides patients with full flexibility in applying VYJUVEK and managing wound dressings.
• The US accounted for the highest total prevalent cases of DEB in the 7MM, with a total of 3,500 cases.
• In 2023, the age bracket most affected by DEB comprised individuals between 1 and 9 years old ~1,300 cases.
• Among the EU4 and the UK countries, the highest number of cases of DEB were in UK ~33%.
• Roughly 48% of DEB cases in 2023 were classified as moderate in severity.
• The leading Dystrophic Epidermolysis Bullosa Companies such as Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others
• Promising Dystrophic Epidermolysis Bullosa Therapies such as VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others

Dystrophic Epidermolysis Bullosa Overview
Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by fragile skin that is prone to blistering and wounding, often in response to minor friction or trauma. It results from mutations in the collagen genes, specifically COL7A1, leading to a deficiency or dysfunction of type VII collagen, which is essential for anchoring the layers of skin together. DEB can vary in severity, with symptoms ranging from mild skin fragility to severe complications, including scarring, deformities, and an increased risk of skin infections and skin cancer. Management focuses on wound care, pain relief, and preventing complications, as there is currently no cure for the condition.

Get a Free sample for the Dystrophic Epidermolysis Bullosa Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation:
• Dystrophic Epidermolysis Bullosa Diagnosed Prevalent Cases
• Dystrophic Epidermolysis Bullosa Age-Specific Cases
• Dystrophic Epidermolysis Bullosa Type-specific Cases
• Dystrophic Epidermolysis Bullosa Severity-specific Cases

Download the report to understand which factors are driving Dystrophic Epidermolysis Bullosa epidemiology trends @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Marketed Drugs

• VYJUVEK (beremagene geperpavec): Krystal Biotech
VYJUVEK is a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy approved for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutations in the collagen type VII alpha 1 chain (COL7A1) gene. It is a topical gel that addresses the genetic cause of DEB by restoring functional copies of the COL7A1 gene to patients. Upon topical application to the wounds, VYJUVEK can transduce both keratinocytes and fibroblasts. Following entry of VYJUVEK into the cells, the vector genome is deposited in the nucleus. Once in the nucleus, 14 transcription of the encoded human COL7A1 is initiated. The resulting transcripts allow for production and secretion of COL7 by the cell in its mature form. These COL7 molecules arrange themselves into long, thin bundles that form anchoring fibrils. The anchoring fibrils hold the epidermis and dermis together and are essential for maintaining the integrity of the skin. Patients with autosomal dominant DEB (DDEB) have lower than normal functional anchoring fibrils, and patients with RDEB have no functional anchoring fibrils. Vyjuvek is the First FDA-approved gene therapy treatment for Dystrophic Epidermolysis Bullosa.

• FILSUVEZ (birch triterpenes): Chiesi
Oleogel-S10 is herbal medicinal product that contains birch triterpenes from birch bark. The drug is a keratinocyte modulator; transient receptor potential channel stimulants are being used to speed up the healing of wounds in adults and children with DEB. The US FDA has granted Rare Pediatric Disease Designation, Fast Track, and Priority Review for the treatment of DEB. Further, it has been granted Orphan Drug Designation by the US FDA and EMA. Oleogel-S10 (Filsuvez) has been approved by the EMA for the treatment of the cutaneous manifestations of DEB.

Dystrophic Epidermolysis Bullosa Therapies and Key Companies
• VYJUVEK (beremagene geperpavec): Krystal Biotech
• FILSUVEZ (birch triterpenes): Chiesi
• PTW-002 10 mg/g gel: Phoenicis Therapeutics
• AGLE 102: Aegle Therapeutics
• ALLO-ASC-SHEET: Anterogen Co., Ltd.
• EB-101: Abeona Therapeutics, Inc
• FCX-007: Castle Creek Bioscience
• PTR-01: Phoenix Tissue Repair, Inc.
• SD-101-6.0 cream: Scioderm, Inc.
• INM-755 (cannabinol) cream: InMed Pharmaceuticals Inc.

Discover more about therapies set to grab major Dystrophic Epidermolysis Bullosa market share @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Market Strengths
• A rising number of clinical trials are underway to assess innovative treatment approaches that have the potential to alter the progression of dystrophic epidermolysis bullosa and relieve its symptoms.
• Gene therapies for dystrophic epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA-approved topical gene therapy

Dystrophic Epidermolysis Bullosa Market Opportunities
• Currently, the lack of a cure and approved treatment presents a significant commercial opportunity for companies active in developing regenerative medicines, that is, cell and gene therapies.
• Significant advancements have been achieved in comprehending the molecular genetics and underlying mechanisms of dystrophic epidermolysis bullosa, laying the groundwork for developing potential treatments.

Scope of the Dystrophic Epidermolysis Bullosa Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others
• Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dystrophic Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Dystrophic Epidermolysis Bullosa Market Access and Reimbursement

To know more about Dystrophic Epidermolysis Bullosa companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Dystrophic Epidermolysis Bullosa Market Report Introduction
2. Executive Summary for Dystrophic Epidermolysis Bullosa
3. SWOT analysis of Dystrophic Epidermolysis Bullosa
4. Dystrophic Epidermolysis Bullosa Patient Share (%) Overview at a Glance
5. Dystrophic Epidermolysis Bullosa Market Overview at a Glance
6. Dystrophic Epidermolysis Bullosa Disease Background and Overview
7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Dystrophic Epidermolysis Bullosa
9. Dystrophic Epidermolysis Bullosa Current Treatment and Medical Practices
10. Dystrophic Epidermolysis Bullosa Unmet Needs
11. Dystrophic Epidermolysis Bullosa Emerging Therapies
12. Dystrophic Epidermolysis Bullosa Market Outlook
13. Country-Wise Dystrophic Epidermolysis Bullosa Market Analysis (2020-2034)
14. Dystrophic Epidermolysis Bullosa Market Access and Reimbursement of Therapies
15. Dystrophic Epidermolysis Bullosa Market Drivers
16. Dystrophic Epidermolysis Bullosa Market Barriers
17. Dystrophic Epidermolysis Bullosa Appendix
18. Dystrophic Epidermolysis Bullosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.